French Cure51 Secures €15M Seed Funding to Revolutionize Cancer Treatment with Survivor Research

By , in BioTech France on .

Unveiling Cure51’s Revolutionary Approach in Cancer Treatment with Techbio Innovations

Cure51, a forward-thinking techbio firm, has recently garnered a substantial €15 million in seed financing to delve into the biological marvels underpinning cancer survivors’ resilience. The company aims to spearhead groundbreaking treatments that could render cancer a conquerable ailment.

This momentous financial infusion, championed by Sofinnova Partners, sees contributions from Hitachi Ventures GmbH, Life Extension Ventures, and tech luminaries Xavier Niel and Olivier Pomel of Datadog. Collaboration with globally acclaimed oncology institutions, including the Gustave Roussy Institute, Leon Bérard Center, Charité Universitätsmedizin, and Vall d’Hebron, further bolsters the endeavour.

Cure51 Dashboard
Cure51 Dashboard

The mission of Cure51 is to decode the elusive biological puzzles that allow certain cancer patients to triumph over particularly virulent strains of the disease. By dissecting these mechanisms, Cure51 aspires to empower all cancer patients to emerge as exceptional survivors, thereby pioneering new avenues in precision medicine and drug discovery. Central to this quest are cutting-edge analytical methods and Cure51’s alliance with premier cancer research centres worldwide.

Nicolas Wolikow, Co-founder and CEO of Cure51, articulates the significance of this funding, envisioning a future where the intricacies of cancer survival are unravelled, thereby saving innumerable lives. Simon Istolainen, Co-founder and Chief Strategy and Scientific Network Officer of Cure51, echoes this sentiment.

Simon Turner, a Partner at Sofinnova Partners, commends Cure51’s innovative approach to understanding exceptional survival in cancer, leveraging advanced analytical techniques at an unprecedented scale. He notes the company’s robust clinical network and ambitious team as key factors driving their investment decision.

Joanna Soroka, PhD, Principal at Hitachi Ventures GmbH, highlights the indispensable role of top-tier datasets in modern AI models for unveiling new biological insights and developing transformative medicines, a unique aspect of Cure51’s approach.

Cure51 cofounders Nicolas Wolikow and Simon Istolainen
Cure51 cofounders Nicolas Wolikow and Simon Istolainen

Cure51, established in March 2022 by Nicolas Wolikow and Simon Istolainen alongside esteemed entrepreneurs and four world-class oncology centres, is pioneering the first global clinical and molecular database of cancer survivors. The focus is on rewriting the cancer narrative, shifting the lens from the disease to the outliers – those individuals who defy the odds and survive the most aggressive cancers, including metastatic pancreatic cancer and glioblastoma.